Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

医学 吉非替尼 内科学 安慰剂 危险系数 临床终点 肺癌 人口 养生 胃肠病学 腺癌 外科 随机对照试验 癌症 置信区间 表皮生长因子受体 病理 替代医学 环境卫生
作者
Nick Thatcher,Alex Y. Chang,Purvish M. Parikh,José Rodrigues Pereira,Tudor‐Eliade Ciuleanu,Joachim von Pawel,Sumitra Thongprasert,E.H. Tan,Kristine Pemberton,Venice Archer,Kevin Carroll
出处
期刊:The Lancet [Elsevier BV]
卷期号:366 (9496): 1527-1537 被引量:2105
标识
DOI:10.1016/s0140-6736(05)67625-8
摘要

Background This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer. Methods 1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care. The primary endpoint was survival in the overall population of patients and those with adenocarcinoma. The primary analysis of the population for survival was by intention to treat. This study has been submitted for registration with ClinicalTrials.gov, number 1839IL/709. Findings 1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7·2 months, median survival did not differ significantly between the groups in the overall population (5·6 months for gefitinib and 5·1 months for placebo; hazard ratio 0·89 [95% CI 0·77–1·02], p=0·087) or among the 812 patients with adenocarcinoma (6·3 months vs 5·4 months; 0·84 [0·68–1·03], p=0·089). Preplanned subgroup analyses showed significantly longer survival in the gefitinib group than the placebo group for never-smokers (n=375; 0·67 [0·49–0·92], p=0·012; median survival 8·9 vs 6·1 months) and patients of Asian origin (n=342; 0·66 [0·48–0·91], p=0·01; median survival 9·5 vs 5·5 months). Gefitinib was well tolerated, as in previous studies. Interpretation Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population. There was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英俊的铭应助wellyou采纳,获得10
2秒前
风中的向卉完成签到 ,获得积分10
5秒前
Mp4完成签到 ,获得积分10
5秒前
凌兰完成签到 ,获得积分10
5秒前
plain完成签到,获得积分10
6秒前
陌上花开完成签到,获得积分10
7秒前
8秒前
fg2477完成签到,获得积分10
9秒前
忙碌的数学人完成签到,获得积分10
9秒前
情怀应助Engen采纳,获得10
9秒前
HJJHJH完成签到,获得积分10
11秒前
Bob发布了新的文献求助10
12秒前
13秒前
14秒前
HJJHJH发布了新的文献求助50
15秒前
JW完成签到,获得积分10
15秒前
wanci应助张参采纳,获得10
16秒前
谦让的西装完成签到 ,获得积分10
17秒前
李演员完成签到,获得积分10
18秒前
fei菲飞完成签到,获得积分10
18秒前
20秒前
Zhaowx完成签到,获得积分10
20秒前
Theprisoners完成签到,获得积分0
20秒前
木子发布了新的文献求助30
20秒前
20秒前
下课了吧完成签到,获得积分10
21秒前
丘比特应助xialuoke采纳,获得10
22秒前
zgt01发布了新的文献求助10
24秒前
linfordlu完成签到,获得积分0
24秒前
清浅发布了新的文献求助10
25秒前
风趣的涵柏完成签到,获得积分10
26秒前
28秒前
Chen完成签到 ,获得积分10
29秒前
30秒前
木樨完成签到,获得积分10
31秒前
科研顺利完成签到,获得积分10
32秒前
Bin完成签到,获得积分10
33秒前
gszy1975发布了新的文献求助10
33秒前
十曰发布了新的文献求助10
34秒前
35秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038235
求助须知:如何正确求助?哪些是违规求助? 3575992
关于积分的说明 11374009
捐赠科研通 3305760
什么是DOI,文献DOI怎么找? 1819276
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022